Idorsia Pharmaceuticals Ltd: Idorsia to further characterize lucerastat for the treatment of Fabry disease by continuing the open-label extension of the Phase 3 MODIFY study

Ad hoc announcement pursuant to Art. 53 LR Idorsia to further characterize lucerastat for the treatment of Fabry disease by continuing the open-label extension of the Phase 3 MODIFY study Idorsia

Related Keywords

Allschwil ,Switzerland General ,Switzerland ,Germany ,Japan ,United Kingdom ,Italy ,France ,Spain ,Japanese ,Swiss ,Andrewc Weiss ,Jean Paul Clozel ,Idorsia Ltd ,Head Of Investor Relations Corporate Communications ,Idorsia Pharmaceuticals Ltd ,Swiss Exchange ,Paul Clozel ,Chief Executive Officer ,Mol Genet ,Vice President ,Investor Relations ,Pharmaceuticals Ltd ,Idorsia ,Pharmaceuticals ,Urther ,Characterize ,Ucerastat ,Treatment ,Dabry ,Disease ,Continuing ,Pen ,Label ,Extension ,Hase ,Codify ,Study ,